Extended resection for potentially operable patients with stage III non–small cell lung cancer after induction treatment

医学 置信区间 危险系数 肺癌 阶段(地层学) 外科 分级(工程) 化疗 诱导化疗 临床试验 癌症 内科学 生物 工程类 土木工程 古生物学
作者
Katarzyna Furrer,Walter Weder,E.I. Eboulet,Daniel Betticher,Miklos Pless,Roger Stupp,Thorsten Krueger,Jean Yannis Perentes,Ralph A. Schmid,Didier Lardinois,Markus Furrer,Martin Früh,Solange Peters,Alessandra Curioni‐Fontecedro,Rolf A. Stahel,Sacha I. Rothschild,Stefanie Hayoz,Isabelle Opitz
出处
期刊:The Journal of Thoracic and Cardiovascular Surgery [Elsevier BV]
卷期号:164 (6): 1587-1602.e5 被引量:19
标识
DOI:10.1016/j.jtcvs.2022.03.034
摘要

Surgical treatment of locally advanced non-small cell lung cancer including single or multilevel N2 remains a matter of debate. Several trials demonstrate that selected patients benefit from surgery if R0 resection is achieved. We aimed to assess resectability and outcome of patients with locally advanced clinical T3/T4 (American Joint Committee on Cancer 8th edition) tumors after induction treatment followed by surgery in a pooled analysis of 3 prospective multicenter trials.A total of 197 patients with T3/T4 non-small cell lung cancer of 368 patients with stage III non-small cell lung cancer enrolled in the Swiss Group for Clinical Cancer Research 16/96, 16/00, 16/01 trials were treated with induction chemotherapy or chemoradiation therapy followed by surgery, including extended resections. Univariable and multivariable analyses were applied for analysis of outcome parameters.Patients' median age was 60 years, and 67% were male. A total of 38 of 197 patients were not resected for technical (81%) or medical (19%) reasons. A total of 159 resections including 36 extended resections were performed with an 80% R0 and 13.2% pathological complete response rate. The 30- and 90-day mortality were 3% and 7%, respectively, without a difference for extended resections. Morbidity was 32% with the majority (70%) of minor grading complications. The 3-, 5-, and 10-year overall survivals for extended resections were 61% (95% confidence interval, 43-75), 44% (95% confidence interval, 27-59), and 29.5% (95% confidence interval, 13-48), respectively. R0 resection was associated with improved overall survival (hazard ratio, 0.41; P < .001), but pretreatment N2 extension (177/197) showed no impact on overall survival.Surgery after induction treatment for advanced T3/T4 stage including single and multiple pretreatment N2 disease resulted in 80% R0 resection rate and 7% 90-day mortality. Favorable overall survival for extended and not extended resection was demonstrated to be independent of pretreatment N status.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
三七完成签到,获得积分10
刚刚
YS0701发布了新的文献求助10
刚刚
1秒前
ih38293发布了新的文献求助10
1秒前
lu乾完成签到,获得积分10
2秒前
2秒前
3秒前
科研通AI6.4应助xinying采纳,获得10
4秒前
4秒前
初遇之时最暖应助YS0701采纳,获得10
5秒前
lu完成签到 ,获得积分10
6秒前
7秒前
轻松幼南发布了新的文献求助30
7秒前
sa完成签到 ,获得积分10
8秒前
chunyeliangchuan完成签到,获得积分10
8秒前
8秒前
Iaint完成签到,获得积分10
8秒前
开心完成签到 ,获得积分10
9秒前
背后的若之完成签到,获得积分10
9秒前
斯文败类应助科研通管家采纳,获得10
10秒前
传奇3应助科研通管家采纳,获得10
10秒前
SciGPT应助科研通管家采纳,获得10
10秒前
10秒前
星辰大海应助科研通管家采纳,获得10
10秒前
10秒前
科研通AI2S应助科研通管家采纳,获得10
10秒前
无极微光应助科研通管家采纳,获得20
10秒前
10秒前
木由子发布了新的文献求助10
10秒前
完美世界应助科研通管家采纳,获得10
10秒前
molihuakai应助科研通管家采纳,获得10
10秒前
JamesPei应助科研通管家采纳,获得10
11秒前
11秒前
尖叫番茄应助科研通管家采纳,获得10
11秒前
丘比特应助科研通管家采纳,获得30
11秒前
Nexus应助科研通管家采纳,获得50
11秒前
脑洞疼应助科研通管家采纳,获得30
11秒前
天天快乐应助科研通管家采纳,获得10
11秒前
11秒前
11秒前
高分求助中
Principles of Economics, 11th Edition 10000
University Physics with Modern Physics, 16th edition 10000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Molecular Mechanisms of Photosynthesis, 4th Edition 1000
Organic Reactions, Volume 116 1000
Matrix Methods in Data Mining and Pattern Recognition 510
Social Skills Improvement System-Rating Scales--Chinese Version 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7254342
求助须知:如何正确求助?哪些是违规求助? 8876192
关于积分的说明 18741419
捐赠科研通 6934864
什么是DOI,文献DOI怎么找? 3200074
关于科研通互助平台的介绍 2374756
邀请新用户注册赠送积分活动 2174923